

PATENT APPLICATION  
DOCKET NO.: LKS95-10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Paul D. Ponath, Douglas J. Ringler, S. Tarran Jones, Walter Newman,  
José Saldanha and Mary M. Bendig

Serial No.:

08/700,737

Group Art Unit: 1804

Filed:


August 15, 1996

Examiner:

For:

HUMANIZED IMMUNOGLOBULIN REACTIVE WITH  $\alpha 4\beta 7$  INTEGRIN

RECEIVED  
MAY 29 1997  
GROUP 1800



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or  
(Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits; whichever occurs last)
- ☐ under 37 CFR 1.97(c) together with either:
- ☐ a Certification under 37 CFR 1.97(e), as checked below, or
- ☐ a \$230.00 fee under 37 CFR 1.17(p), or  
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Certification under 37 CFR 1.97(e), as checked below, and
- ☐ a petition under 37 CFR 1.97(d)(2), and
- ☐ a \$130.00 petition fee set forth in 37 CFR 1.17(i).  
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

Certification Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office

in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Enclosed herewith is form PTO-1449:

- ☒ Copies of the cited references AD-AE, AN-AM2 and AX2-AY4 are enclosed.
- ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Serial No. \_\_\_\_\_, and references that are not required to be submitted under 37 CFR 1.98.
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

Concise Explanation Requirement (non-English references):

- ☐ The "concise explanation" requirement for reference(s) \_\_\_\_\_ under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ abstract.

Method of payment:

- ☐ Enclosed is a check in the amount of \$ \_\_\_\_\_.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$ \_\_\_\_\_.
- ☐ Two duplicate copies of this Statement are enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

REMARKS

The Examiner's attention is also directed to copending U.S. Serial Nos. 08/386,857, filed February 10, 1995 and 08/523,004, filed September 1, 1995. It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

By Helen E. Wendler  
Helen E. Wendler  
Attorney for Applicants  
Registration No.: 37,964  
Telephone: (617) 861-6240

Lexington, Massachusetts 02173

Dated: May 9, 1997